peter-ho.jpg

Peter Ho, MD, PhD

Chief Medical Officer

Peter joined Boston Pharmaceuticals in 2018 from Epizyme, where as Chief Medical Officer he led the company’s clinical development, translational research and regulatory affairs functions. Prior to Epizyme, Peter was Co-Founder and President of BeiGene Ltd. His previous pharmaceutical positions included Vice President of Oncology Clinical Development at Johnson and Johnson and Senior Vice President of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. Peter began his career in drug discovery and development at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, National Cancer Institute (NCI) followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals.

Over his career, Peter has been directly responsible for the first-in-human dosing of 18 anticancer agents and has overseen the development of over 60 investigational compounds, and his work has contributed to ten NCE or biologics approvals to date, including Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®; Synribo®; Tafinlar®; Mekinist®; Sylvant®, and Rydap®.

He completed his pediatrics residency at The Children's Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. Food and Drug Administration (FDA) and the NCI. In addition to his role at Boston Pharmaceuticals, Peter serves on the Scientific Advisory Board of Accent Therapeutics and served as a member of the Pediatric Cancer Working Group of the Cancer Moonshot Task Force.

Peter received a B.A. in biology from The Johns Hopkins University, and MD and PhD degrees from Yale University.